Two-Drug Class HIV Startup Regimens Compared for Weight Gain in Trial
Start here
A randomized clinical trial enrolled treatment-naive adults with HIV to compare weight gain and viral suppression between two initial regimens: doravirine, lamivudine, and tenofovir disoproxil fumarate versus dolutegravir, emtricitabine, and tenofovir alafenamide. The question matters because integrase inhibitor–based regimens such as dolutegravir have been linked to treatment-associated weight gain, and the trial asks whether a non-nucleoside reverse transcriptase inhibitor–based alternative limits it while preserving virologic efficacy. The available data are abstract-level only, with no reported figures yet for weight change or rates of viral suppression in either arm. Full results, including the magnitude of any weight difference and whether the regimens differ in achieving suppression, have not been published.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- JAMA NetworkInitial HIV Therapy for Adults and Treatment-Associated Weight Gain
A randomized clinical trial in treatment-naive adults with HIV compared a regimen of doravirine, lamivudine, and tenofovir disoproxil fumarate against a regimen of dolutegravir, emtricitabine, and tenofovir alafenamide for effects on weight gain and viral suppression. The current material is a summary-level description and does not report specific weight change or virologic suppression results.
Coverage and heat for this story
Reports so far 2·Heat now 6·Peak heat 10 (Oct 20 08:00)·Reports, 24h +2
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.